17 results on '"van Eijck, Casper Hj"'
Search Results
2. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
- Author
-
Van Hilst, Jony, De Rooij, Thijs, Bosscha, Koop, Brinkman, David J, Van Dieren, Susan, Dijkgraaf, Marcel G, Gerhards, Michael F, De Hingh, Ignace H, Karsten, Tom M, Lips, Daniel J, Luyer, Misha D, Busch, Olivier R, Festen, Sebastiaan, Besselink, Marc G, Marsman, Hendrik A, Van Gulik, Thomas M, Wicherts, Dennis A, Eshuis, Wietse J, Stibbe, Luna A, Nieveen van Dijkum, Els JM, Van Hooft, Janine E, Fockens, Paul, Van Laarhoven, Hanneke W, Wilmink, Johanna W, Van de Vijver, Marcel J, Bijlsma, Maarten F, Verheij, Joanne, Nio, C Yung, Van Lienden, Krijn P, Van Tienhoven, Geertjan, Schoorlemmer, Annuska, Creemers, Geert-Jan, Van Eijck, Casper HJ, Groot Koerkamp, Bas, Bruno, Marco J, Eskens, Ferry, Nuyttens, Joost J, Pek, Chulja, Van der Schelling, George P, Seerden, Tom C, Patijn, Gijs A, Nieuwenhuijs, Vincent B, De Groot, Jan W, Bonsing, Bert A, Vahrmeijer, Alexander, Swijnenburg, Rutger J, Mieog, J Sven D, Van der Harst, Erwin, Den Dulk, Marcel, Olde Damink, Steven, Dejong, Cees HC, Van Dam, Ronald, De Vos, Judith MPGM, Liem, Mike SL, Van Laarhoven, Cees JHM, Van Goor, Harry, Van den Boezem, Peter B, Van der Kolk, B Marion, Stommel, Martijn WJ, Hermans, John J, Van Geenen, Erwin JM, Radema, Sandra A, Brosens, Lodewijk A, Scheepers, Joris JG, Roos, Daphne, Boerma, Djamilla, Te Riele, Wouter, Van Santvoort, Hjalmar C, Bollen, Thomas L, Wit, Fanny, Molenaar, I Quintus, Haj Mohammad, Nadia, Van Leeuwen, Maarten S, Roele, Annemarie, De Jong, Kees P, De Meijer, Vincent E, Klaase, Joost M, Kazemier, Geert, Zonderhuis, Babs, Daams, Freek, Meijerink, Martijn R, Latenstein, Anouk, Van Rijssen, L Bengt, Nota, Carolijn, Van Halsema, Emo, Van Veldhuisen, Eran, Vogel, Jantien, Janssen, Kiki, Scholten, Lianne, Daamen, Lois, Walma, Marieke, Strijker, Marin, Prins, Mariska, Zwart, Maurice, Suker, Mustafa, Rombouts, Steffi, Mungroop, Timothy, Vissers, Frederique, Korrel, Maarten, van Hilst, Jony, de Rooij, Thijs, van Dieren, Susan, and de Hingh, Ignace H
- Published
- 2019
- Full Text
- View/download PDF
3. Comparison of lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis
- Author
-
Boxhoorn, Lotte, primary, Verdonk, Robert C, additional, Besselink, Marc G, additional, Boermeester, Marja, additional, Bollen, Thomas L, additional, Bouwense, Stefan AW, additional, Cappendijk, Vincent C, additional, Curvers, Wouter L, additional, Dejong, Cornelis H, additional, van Dijk, Sven M, additional, van Dullemen, Hendrik M, additional, van Eijck, Casper HJ, additional, van Geenen, Erwin JM, additional, Hadithi, Muhammed, additional, Hazen, Wouter L, additional, Honkoop, Pieter, additional, van Hooft, Jeanin E, additional, Jacobs, Maarten AJM, additional, Kievits, June EC, additional, Kop, Marnix PM, additional, Kouw, Eva, additional, Kuiken, Sjoerd D, additional, Ledeboer, Michiel, additional, Nieuwenhuijs, Vincent B, additional, Perk, Lars E, additional, Poley, Jan-Werner, additional, Quispel, Rutger, additional, de Ridder, Rogier JJ, additional, van Santvoort, Hjalmar C, additional, Sperna Weiland, Christina J, additional, Stommel, Martijn WJ, additional, Timmerhuis, Hester C, additional, Witteman, Ben J, additional, Umans, Devica S, additional, Venneman, Niels G, additional, Vleggaar, Frank P, additional, van Wanrooij, Roy LJ, additional, Bruno, Marco J, additional, Fockens, Paul, additional, and Voermans, Rogier P, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Comparison of lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis
- Author
-
Boxhoorn, Lotte, Verdonk, Robert C, Besselink, Marc G, Boermeester, Marja, Bollen, Thomas L, Bouwense, Stefan AW, Cappendijk, Vincent C, Curvers, Wouter L, Dejong, Cornelis H, van Dijk, Sven M, van Dullemen, Hendrik M, van Eijck, Casper HJ, van Geenen, Erwin JM, Hadithi, Muhammed, Hazen, Wouter L, Honkoop, Pieter, van Hooft, Jeanin E, Jacobs, Maarten AJM, Kievits, June EC, Kop, Marnix PM, Kouw, Eva, Kuiken, Sjoerd D, Ledeboer, Michiel, Nieuwenhuijs, Vincent B, Perk, Lars E, Poley, Jan-Werner, Quispel, Rutger, de Ridder, Rogier JJ, van Santvoort, Hjalmar C, Sperna Weiland, Christina J, Stommel, Martijn WJ, Timmerhuis, Hester C, Witteman, Ben J, Umans, Devica S, Venneman, Niels G, Vleggaar, Frank P, van Wanrooij, Roy LJ, Bruno, Marco J, Fockens, Paul, and Voermans, Rogier P
- Abstract
ObjectiveLumen-apposing metal stents (LAMS) are believed to clinically improve endoscopic transluminal drainage of infected necrosis when compared with double-pigtail plastic stents. However, comparative data from prospective studies are very limited.DesignPatients with infected necrotising pancreatitis, who underwent an endoscopic step-up approach with LAMS within a multicentre prospective cohort study were compared with the data of 51 patients in the randomised TENSION trial who had been assigned to the endoscopic step-up approach with double-pigtail plastic stents. The clinical study protocol was otherwise identical for both groups. Primary end point was the need for endoscopic transluminal necrosectomy. Secondary end points included mortality, major complications, hospital stay and healthcare costs.ResultsA total of 53 patients were treated with LAMS in 16 hospitals during 27 months. The need for endoscopic transluminal necrosectomy was 64% (n=34) and was not different from the previous trial using plastic stents (53%, n=27)), also after correction for baseline characteristics (OR 1.21 (95% CI 0.45 to 3.23)). Secondary end points did not differ between groups either, which also included bleeding requiring intervention—5 patients (9%) after LAMS placement vs 11 patients (22%) after placement of plastic stents (relative risk 0.44; 95% CI 0.16 to 1.17). Total healthcare costs were also comparable (mean difference −€6348, bias-corrected and accelerated 95% CI −€26 386 to €10 121).ConclusionOur comparison of two patient groups from two multicentre prospective studies with a similar design suggests that LAMS do not reduce the need for endoscopic transluminal necrosectomy when compared with double-pigtail plastic stents in patients with infected necrotising pancreatitis. Also, the rate of bleeding complications was comparable.
- Published
- 2023
- Full Text
- View/download PDF
5. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
- Author
-
Besselink, Marc GH, van Santvoort, Hjalmar C, Buskens, Erik, Boermeester, Marja A, van Goor, Harry, Timmerman, Harro M, Nieuwenhuijs, Vincent B, Bollen, Thomas L, van Ramshorst, Bert, Witteman, Ben JM, Rosman, Camiel, Ploeg, Rutger J, Brink, Menno A, Schaapherder, Alexander FM, Dejong, Cornelis HC, Wahab, Peter J, van Laarhoven, Cees JHM, van der Harst, Erwin, van Eijck, Casper HJ, Cuesta, Miguel A, Akkermans, Louis MA, and Gooszen, Hein G
- Published
- 2008
- Full Text
- View/download PDF
6. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review
- Author
-
Kuipers Ernst J, Steyerberg Ewout W, van Eijck Casper HJ, Jeurnink Suzanne M, and Siersema Peter D
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Gastrojejunostomy (GJJ) is the most commonly used palliative treatment modality for malignant gastric outlet obstruction. Recently, stent placement has been introduced as an alternative treatment. We reviewed the available literature on stent placement and GJJ for gastric outlet obstruction, with regard to medical effects and costs. Methods A systematic review of the literature was performed by searching PubMed for the period January 1996 and January 2006. A total of 44 publications on GJJ and stents was identified and reported results on medical effects and costs were pooled and evaluated. Results from randomized and comparative studies were used for calculating odds ratios (OR) to compare differences between the two treatment modalities. Results In 2 randomized trials, stent placement was compared with GJJ (with 27 and 18 patients in each trial). In 6 comparative studies, stent placement was compared with GJJ. Thirty-six series evaluated either stent placement or GJJ. A total of 1046 patients received a duodenal stent and 297 patients underwent GJJ. No differences between stent placement and gastrojejunostomy were found in technical success (96% vs. 100%), early and late major complications 7% vs. 6% and 18% vs. 17%, respectively) and persisting symptoms (8% vs. 9%). Initial clinical success was higher after stent placement (89% vs. 72%). Minor complications were less frequently seen after stent placement in the patient series (9% vs. 33%), however the pooled analysis showed no differences (OR: 0.75, p = 0.8). Recurrent obstructive symptoms were more common after stent placement (18% vs. 1%). Hospital stay was prolonged after GJJ compared to stent placement (13 days vs. 7 days). The mean survival was 105 days after stent placement and 164 days after GJJ. Conclusion These results suggest that stent placement may be associated with more favorable results in patients with a relatively short life expectancy, while GJJ is preferable in patients with a more prolonged prognosis. The paucity of evidence from large randomized trials may however have influenced the results and therefore a trial of sufficient size is needed to determine which palliative treatment modality is optimal in (sub)groups of patients with malignant gastric outlet obstruction.
- Published
- 2007
- Full Text
- View/download PDF
7. Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DRainage vs. (direct) OPeration (DROP-trial)
- Author
-
Sosef Meindert N, van der Harst Erwin, Kubben Frank JGM, van Laarhoven Cees J, Bonsing Bert A, Boerma Djamila, Rinkes Inne, Klinkenbijl Jean HG, Hesselink Erik J, Greve Jan, Rutten Jan-Paul, Gerritsen Josephus JGM, Kuipers Ernst J, van Eijck Casper HJ, Bruno Marco J, Rauws Erik AJ, de Castro Steve MM, van der Gaag Niels A, Bosscha Koop, de Hingh Ignace HJT, Th de Wit Laurens, van Delden Otto M, Busch Olivier RC, van Gulik Thomas M, Bossuyt Patrick MM, and Gouma Dirk J
- Subjects
Surgery ,RD1-811 - Abstract
Abstract Background Surgery in patients with obstructive jaundice caused by a periampullary (pancreas, papilla, distal bile duct) tumor is associated with a higher risk of postoperative complications than in non-jaundiced patients. Preoperative biliary drainage was introduced in an attempt to improve the general condition and thus reduce postoperative morbidity and mortality. Early studies showed a reduction in morbidity. However, more recently the focus has shifted towards the negative effects of drainage, such as an increase of infectious complications. Whether biliary drainage should always be performed in jaundiced patients remains controversial. The randomized controlled multicenter DROP-trial (DRainage vs. Operation) was conceived to compare the outcome of a 'preoperative biliary drainage strategy' (standard strategy) with that of an 'early-surgery' strategy, with respect to the incidence of severe complications (primary-outcome measure), hospital stay, number of invasive diagnostic tests, costs, and quality of life. Methods/design Patients with obstructive jaundice due to a periampullary tumor, eligible for exploration after staging with CT scan, and scheduled to undergo a "curative" resection, will be randomized to either "early surgical treatment" (within one week) or "preoperative biliary drainage" (for 4 weeks) and subsequent surgical treatment (standard treatment). Primary outcome measure is the percentage of severe complications up to 90 days after surgery. The sample size calculation is based on the equivalence design for the primary outcome measure. If equivalence is found, the comparison of the secondary outcomes will be essential in selecting the preferred strategy. Based on a 40% complication rate for early surgical treatment and 48% for preoperative drainage, equivalence is taken to be demonstrated if the percentage of severe complications with early surgical treatment is not more than 10% higher compared to standard treatment: preoperative biliary drainage. Accounting for a 10% dropout, 105 patients are needed in each arm resulting in a study population of 210 (alpha = 0.95, beta = 0.8). Discussion The DROP-trial is a randomized controlled multicenter trial that will provide evidence whether or not preoperative biliary drainage is to be performed in patients with obstructive jaundice due to a periampullary tumor.
- Published
- 2007
- Full Text
- View/download PDF
8. Minimally invasive 'step-up approach' versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868]
- Author
-
Houdijk Lex PJ, Hesselink Eric J, van der Harst Erwin, Gouma Dirk J, Consten Esther CJ, Cuesta Miguel A, Schaapherder Alexander FM, van Ramshorst Bert, Ploeg Rutger J, van Leeuwen Maarten S, Lameris Johan S, Hofker Sijbrand S, van Goor Harry, van Eijck Casper HJ, Dejong Cornelis HC, Buskens Erik, Bollen Thomas L, Boermeester Marja A, Nieuwenhuijs Vincent B, van Santvoort Hjalmar C, Besselink Marc GH, Karsten Tom M, van Laarhoven Cees JHM, Pierie Jean-Pierre EN, Rosman Camiel, Bilgen Ernst, Timmer Robin, van der Tweel Ingeborg, de Wit Ralph J, Witteman Ben JM, and Gooszen Hein G
- Subjects
Surgery ,RD1-811 - Abstract
Abstract Background The initial treatment of acute necrotizing pancreatitis is conservative. Intervention is indicated in patients with (suspected) infected necrotizing pancreatitis. In the Netherlands, the standard intervention is necrosectomy by laparotomy followed by continuous postoperative lavage (CPL). In recent years several minimally invasive strategies have been introduced. So far, these strategies have never been compared in a randomised controlled trial. The PANTER study (PAncreatitis, Necrosectomy versus sTEp up appRoach) was conceived to yield the evidence needed for a considered policy decision. Methods/design 88 patients with (suspected) infected necrotizing pancreatitis will be randomly allocated to either group A) minimally invasive 'step-up approach' starting with drainage followed, if necessary, by videoscopic assisted retroperitoneal debridement (VARD) or group B) maximal necrosectomy by laparotomy. Both procedures are followed by CPL. Patients will be recruited from 20 hospitals, including all Dutch university medical centres, over a 3-year period. The primary endpoint is the proportion of patients suffering from postoperative major morbidity and mortality. Secondary endpoints are complications, new onset sepsis, length of hospital and intensive care stay, quality of life and total (direct and indirect) costs. To demonstrate that the 'step-up approach' can reduce the major morbidity and mortality rate from 45 to 16%, with 80% power at 5% alpha, a total sample size of 88 patients was calculated. Discussion The PANTER-study is a randomised controlled trial that will provide evidence on the merits of a minimally invasive 'step-up approach' in patients with (suspected) infected necrotizing pancreatitis.
- Published
- 2006
- Full Text
- View/download PDF
9. Oncolytic viruses: From bench to bedside with a focus on safety
- Author
-
Buijs, Pascal RA, primary, Verhagen, Judith HE, additional, van Eijck, Casper HJ, additional, and van den Hoogen, Bernadette G, additional
- Published
- 2015
- Full Text
- View/download PDF
10. Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial
- Author
-
Wiggers, Jimme K, primary, Coelen, Robert JS, additional, Rauws, Erik AJ, additional, van Delden, Otto M, additional, van Eijck, Casper HJ, additional, de Jonge, Jeroen, additional, Porte, Robert J, additional, Buis, Carlijn I, additional, Dejong, Cornelis HC, additional, Molenaar, I Quintus, additional, Besselink, Marc GH, additional, Busch, Olivier RC, additional, Dijkgraaf, Marcel GW, additional, and van Gulik, Thomas M, additional
- Published
- 2015
- Full Text
- View/download PDF
11. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review
- Author
-
Jeurnink, Suzanne M, primary, van Eijck, Casper HJ, additional, Steyerberg, Ewout W, additional, Kuipers, Ernst J, additional, and Siersema, Peter D, additional
- Published
- 2007
- Full Text
- View/download PDF
12. Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DR ainage vs. (direct) OP eration (DROP-trial)
- Author
-
van der Gaag, Niels A, primary, de Castro, Steve MM, additional, Rauws, Erik AJ, additional, Bruno, Marco J, additional, van Eijck, Casper HJ, additional, Kuipers, Ernst J, additional, Gerritsen, Josephus JGM, additional, Rutten, Jan-Paul, additional, Greve, Jan Willem, additional, Hesselink, Erik J, additional, Klinkenbijl, Jean HG, additional, Rinkes, Inne HM Borel, additional, Boerma, Djamila, additional, Bonsing, Bert A, additional, van Laarhoven, Cees J, additional, Kubben, Frank JGM, additional, van der Harst, Erwin, additional, Sosef, Meindert N, additional, Bosscha, Koop, additional, de Hingh, Ignace HJT, additional, Th de Wit, Laurens, additional, van Delden, Otto M, additional, Busch, Olivier RC, additional, van Gulik, Thomas M, additional, Bossuyt, Patrick MM, additional, and Gouma, Dirk J, additional
- Published
- 2007
- Full Text
- View/download PDF
13. Minimally invasive 'step-up approach' versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN38327949]
- Author
-
Besselink, Marc GH, van Santvoort, Hjalmar C, Nieuwenhuijs, Vincent B, Boermeester, Marja A, Bollen, Thomas L, Buskens, Erik, Dejong, Cornelis HC, van Eijck, Casper HJ, van Goor, Harry, Hofker, Sijbrand S, Lameris, Johan S, van Leeuwen, Maarten S, Ploeg, Rutger J, van Ramshorst, Bert, Schaapherder, Alexander FM, Cuesta, Miguel A, Consten, Esther CJ, Gouma, Dirk J, van der Harst, Erwin, Hesselink, Eric J, Houdijk, Lex PJ, Karsten, Tom M, van Laarhoven, Cees JHM, Pierie, Jean-Pierre EN, Rosman, Camiel, Bilgen, Ernst Jan Spillenaar, Timmer, Robin, van der Tweel, Ingeborg, de Wit, Ralph J, Witteman, Ben JM, and Gooszen, Hein G
- Subjects
Postoperative Care ,Pathogenesis and modulation of inflammation [N4i 1] ,Study Protocol ,Laparotomy ,Pancreatitis, Acute Necrotizing ,Evaluation of complex medical interventions [NCEBP 2] ,Drainage ,Humans ,Video-Assisted Surgery ,Microbial pathogenesis and host defense [UMCN 4.1] ,Therapeutic Irrigation - Abstract
Contains fulltext : 49444.pdf ( ) (Open Access) BACKGROUND: The initial treatment of acute necrotizing pancreatitis is conservative. Intervention is indicated in patients with (suspected) infected necrotizing pancreatitis. In the Netherlands, the standard intervention is necrosectomy by laparotomy followed by continuous postoperative lavage (CPL). In recent years several minimally invasive strategies have been introduced. So far, these strategies have never been compared in a randomised controlled trial. The PANTER study (PAncreatitis, Necrosectomy versus sTEp up appRoach) was conceived to yield the evidence needed for a considered policy decision. METHODS/DESIGN: 88 patients with (suspected) infected necrotizing pancreatitis will be randomly allocated to either group A) minimally invasive 'step-up approach' starting with drainage followed, if necessary, by videoscopic assisted retroperitoneal debridement (VARD) or group B) maximal necrosectomy by laparotomy. Both procedures are followed by CPL. Patients will be recruited from 20 hospitals, including all Dutch university medical centres, over a 3-year period. The primary endpoint is the proportion of patients suffering from postoperative major morbidity and mortality. Secondary endpoints are complications, new onset sepsis, length of hospital and intensive care stay, quality of life and total (direct and indirect) costs. To demonstrate that the 'step-up approach' can reduce the major morbidity and mortality rate from 45 to 16%, with 80% power at 5% alpha, a total sample size of 88 patients was calculated. DISCUSSION: The PANTER-study is a randomised controlled trial that will provide evidence on the merits of a minimally invasive 'step-up approach' in patients with (suspected) infected necrotizing pancreatitis.
- Published
- 2006
14. Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3.
- Author
-
Haddaoui HE, van Eijck CW, Doukas M, van den Bosch TP, van Koetsveld PM, Hofland LJ, Mustafa DA, and van Eijck CH
- Abstract
Pancreatic cancer has a dismal prognosis, and treatment options for patients with locally advanced or metastatic disease are limited. Early tumor progression after standard chemo- and or radiotherapy remains a major concern in managing these patients. Treating pancreatic cancer patients with the Toll-like receptor 3 (TLR-3) agonist rintatolimod (Ampligen
® ) was effective in boosting the immune response. Rintatolimod acts via the TLR-3 receptor on several immune cells. However, the TLR-3 expression pattern in pancreatic cancer cells and how rintatolimod affects pancreatic cancer cells have not yet been investigated. The TLR-3 protein and mRNA expression were evaluated in thirteen PDAC tissue samples as well as in the human PDAC (hPDAC) cell lines CFPAC-1, MIAPaCa-2, and PANC-1 using immunohistochemistry and multiplexed gene expression analysis, respectively. The direct anti-tumor effects of rintatolimod were investigated using a proliferation and migration assay after different incubation time points with increasing concentrations of rintatolimod (ranging from 0.05 to 0.4 mg/ml). The TLR-3 protein and mRNA expression were heterogeneous between the PDAC tissue samples and the three hPDAC cell lines. TLR-3 protein and mRNA expression were high in CFPAC-1, moderate in MIAPaCa-2, and undetectable in PANC-1. Rintatolimod three-day treatment resulted in significantly reduced proliferation of CFPAC-1 cells compared to vehicle-treated control cells. In addition, after 24 hours, rintatolimod-treated CFPAC-1 cells showed less cell migration compared to vehicle-treated control cells, although this difference was not statistically significant. Lastly, we identified fifteen genes, altered with a Log2 FOC > |1.0| in rintatolimod-treated CFPAC-1 cells, which were significantly related to three transcription factors (NFKB1, RELA, and SP1) regulating the TLR-3 signaling pathway. In conclusion, we propose that rintatolimod treatment might have a direct TLR-3-dependent anti-tumoral effect on pancreatic cancer cells expressing TLR-3., Competing Interests: None., (AJCR Copyright © 2023.)- Published
- 2023
15. Patients with chronic mesenteric ischemia have an altered sublingual microcirculation.
- Author
-
Harki J, Suker M, Tovar-Doncel MS, van Dijk LJ, van Noord D, van Eijck CH, Bruno MJ, Kuipers EJ, and Ince C
- Abstract
Background: Little is known about the microcirculatory alterations in patients with chronic mesenteric ischemia (CMI). We hypothesized that patients with CMI have an impaired microcirculatory function and show an oral microcirculatory response after caloric challenge compared to healthy controls., Methods: All patients and controls received the standard workup for CMI. Sublingual micro-circulation was evaluated before (T0) and 20 minutes after (T1) feeding. The total vessel density (TVD; mm/mm
2 ), perfused vessel density (PVD; mm/mm2 ), proportion of perfused vessels (PPV; %) and microvascular flow index (MFI; AU) were assessed., Results: We included 12 patients (63.2 years [IQR 48.8-70.4 years], 67% males) and 12 controls (32.7 years [IQR 27.7-38.1 years], 42% males). At baseline, patients with CMI had a decreased PPV of the sublingual small vessels (median 84.8% vs 95.7%, P =0.006), PPV of all vessels (PPV median 85.4% vs 95.3%, P =0.007) and microvascular flow index of all vessels (MFIa; median 3.00 vs 2.80, P =0.039) compared to healthy controls. After caloric challenge, PVD increased significantly in both small vessels (perfused vessel density of the small vessels [PVDs]) and all vessels (perfused vessel density of all vessels [PVDa]; PVDs [T0]) median 16.3 [IQR 13.3-22.1] vs [T1] median 19.9 [IQR 14.2-26.2], P =0.008; PVDa [T0] median 19.1 [IQR 16.2-23.6] vs [T1] median 22.2 [IQR 16.5-28.9], P =0.02; proportion of perfused vessels of the small vessels (PPVs; [T0] median 84.8% [IQR 75.3-90.4] vs [T1] median 91.0% [IQR 80.1-93.8], P =0.010). In contrast, no significant changes in microcirculatory parameters were observed after caloric challenge in healthy controls., Conclusion: Patients with CMI have an impaired sublingual microcirculation at baseline and show a significant response in the sublingual microcirculation after caloric challenge, whereas healthy controls have a normal microcirculation at baseline and show no reactive response upon a caloric challenge as seen in CMI patients. Sublingual microcirculation visualization may offer a rapid noninvasive method to identify patients at risk for having CMI., Competing Interests: Disclosure Professor Ince has developed stream dark field imaging, the predecessor of the device used in this study, and is listed as an inventor on related patents commercialized by MicroVision Medical (MVM) under a license from the Academic Medical Center in Amsterdam, the Netherlands. He has been a consultant for MVM in the past but has not been involved with this company for >5 years now and holds no shares. Braedius Medical, a company owned by a relative of Professor Ince, has developed and designed a handheld microscope called CytoCam-IDF imaging used in this study. Professor Ince has no financial relation with Braedius Medical of any sort, ie, never owned shares, or received consultancy or speaker fees from Braedius Medical. The authors report no other conflicts of interest in this work.- Published
- 2018
- Full Text
- View/download PDF
16. Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer.
- Author
-
Vietsch EE, van Eijck CH, and Wellstein A
- Abstract
Collecting repeat samples of blood ("liquid biopsies") is a broadly used clinical approach for serial monitoring of disease or response to treatments. In patients with cancer the most distinct molecular feature are somatic mutations acquired by cancer cells present in the diseased tissue. Indeed, mutant DNA derived from dying or lysed cancer cells can be isolated from patient serum samples, subjected to DNA sequencing and to analysis of abundance as a measure of tumor burden. Also, changes in the DNA mutation patterns in serum samples collected over time can indicate altered pathways or clonal evolution of the disease and altered abundance of mutant DNA suggests an altered disease burden. In addition, during the course of treatment, changes in circulating DNA mutation patterns can indicate the emergence of resistant clones and prompt changes in treatment. In contrast to mutant DNA, microRNAs (miR) are transcribed, processed, packaged and released from cells in normal and in diseased tissues as part of the extracellular crosstalk between cells. Interestingly, released miR can function in cell-to-cell communication and as hormone-like signals that operate at a distance through their release into the circulation and subsequent uptake into cells in distant tissues. Circulating miR expression patterns can be established from serial serum samples and monitored for alterations over time. Circulating miR provide a readout of the organism's steady state and serial analyses will indicate changes in the response to therapy or an altered physiologic or disease state. Furthermore, changes in circulating miR patterns can indicate treatment efficacy or resistance as well as adverse effects associated with the respective intervention. Thus, the combined serial analysis of mutant DNA and miR in the circulation has the potential to provide a molecular footprint of pancreatic cancer and can be used to monitor treatment responses or resistance to treatment in real time with a minimally invasive procedure.
- Published
- 2015
- Full Text
- View/download PDF
17. IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells.
- Author
-
Booy S, van Eijck CH, Janssen JA, Dogan F, van Koetsveld PM, and Hofland LJ
- Abstract
Introduction: Pancreatic cancer is a highly aggressive malignancy with few treatment options. The overexpression of several growth factors, including insulin and insulin-like growth factors (IGFs), can underlie the aggressive nature of this disease. Previous research has demonstrated potent effects of interferon (IFN)-β on pancreatic cancer cell growth, however up till now it is unknown whether IFN-β is able to counteract IGF1, IGF2 and insulin-induced pancreatic cancer cell proliferation and migration., Methods: Expression of IGF- and insulin receptors was determined and the stimulatory effects of IGF1, IGF2 and insulin on cell proliferation and migration, as well as the inhibitory effects of IFN-β were evaluated in 3 human pancreatic adenocarcinoma cell lines., Results: Both the insulin- and the IGF1 receptor were variably expressed in the cell lines. IGF1, IGF2 and insulin were capable of stimulating cell proliferation in all three cell lines, however cell migration was significantly enhanced only in the BxPC-3 cell line. IFN-β significantly inhibited IGF1-, IGF2- and insulin-stimulated proliferation in all three cell lines in a dose and time dependent manner. Furthermore, in the BxPC-3 cell line IFN-β significantly inhibited both basal and IGF1-, IGF2- and insulin-stimulated cell migration., Conclusion: Both IGF1, -2 and insulin were capable of stimulating proliferation and migration in human pancreatic cancer cells irrespective of the type of receptor expressed. This study demonstrates that insulin, in addition to IGF1 and IGF2, may play an important role in the progression of pancreatic cancer. Moreover, IFN-β strongly inhibits growth factor stimulated cell proliferation and migration. Our study supports previous findings which have suggested that IFN-β can be a potential promising anti-cancer agent in pancreatic cancer.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.